April 21, 2020
Schwendinger M et al. J Infect Dis 2020;jiaa121.
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus
You might also be interested by
CellTalk Blog
ELISpot vs. ICS: Optimizing Immune Monitoring in Clinical Trials with the Right Functional Assay
November 19, 2024
Immune Monitoring
More infoCellTalk Blog
Measure Target Engagement With Receptor Occupancy Assays by Flow Cytometry
September 17, 2024
Immune Monitoring
More infoBrochures & Infographics
High Performance Technologies for Cytokine Measurement
July 29, 2024
Immune Monitoring
More info